20 G vitrectomy safe and effective technique in vitreoretinal surgery

Article

Using twenty-gauge transconjunctival sutureless vitrectomy in vitreoretinal surgery is a safe and effective treatment for a variety of vitreoretinal pathologies

Using twenty-gauge transconjunctival sutureless vitrectomy in vitreoretinal surgery is a safe and effective treatment for a variety of vitreoretinal pathologies, according to a study featured in Retina.

The retrospective study led by Dr Oriel Spierer, Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Israel, reviewed the charts of 102 consecutive patients who experienced 20-gauge transconjunctival sutureless vitrectomy performed by a single surgeon.

All patients were assessed preoperatively and 1 day, 1 month and 3 months postoperatively. The main outcome measures included intraoperative/postoperative intraocular pressure and Snellen visual acuity compared to preoperative data.

Findings revealed that two patients needed suturing of 1 scleretomy due to postoperative leakage. The mean preoperative visual acuity was 1.1 ± 0.6. Three months postoperatively the mean visual acuity was 0.8 ± 0.5.

Mean preoperative intraocular pressure was 14.7 ± 5.1 mmHg, whilst postoperatively it was 14.2 ± 5.5 mmHg and 14.6 ± 4.3 mmHg at day 1 and day 7, respectively.

In three patients hypotony was found on the first day postoperatively, but intraocular pressure returned to normal within a week. There was no record of postoperative endophthalmitis or retinal detachment in any of the patients.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.